Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

A role for IFN-λ1 in multiple myeloma B cell growth

Leukemia volume 22, pages 2240–2246 (2008)Cite this article

Abstract

Multiple myeloma (MM) is a progressive disease that results from dysregulated proliferation of plasma cells. Although, causative factors such as genetic events and altered expression of anti-apoptotic factors have been described in a number of patients, the mechanistic details that drive myeloma development and continued growth of malignant cells remain largely undefined. Numerous growth factors, including interleukin (IL)-6, Insulin-like growth factor-1 and IL-10 have been shown to promote growth of MM cells suggesting a significant role for cytokines in this disease. Interferon (IFN)-λ1 is a new member of the Class II cytokine family that, similar to IFN-α, has been shown to mediate viral immunity. In light of data supporting a role for cytokines in myeloma, we investigated the significance of IFN-λ1 on myeloma cell biology. Our studies show for the first time that myeloma cells bind to soluble IFN-λ1, and that IFN-λ1 induces myeloma cell growth and protects against dexamethasone-induced cell death. Our data also show that IFN-λ1 induces phosphorylation of STAT1, STAT3 and Erk. Taken together, our results suggest that IFN-λ1 may regulate myeloma cell biology and could prove to be therapeutically important.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69–77.

    Article  CAS  PubMed  Google Scholar 

  2. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63–68.

    Article  CAS  PubMed  Google Scholar 

  3. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC . Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 2004; 279: 32269–32274.

    Article  CAS  PubMed  Google Scholar 

  4. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M . Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 2005; 31: 109–118.

    Article  CAS  PubMed  Google Scholar 

  5. Pestka S, Krause CD, Walter MR . Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202: 8–32.

    Article  CAS  PubMed  Google Scholar 

  6. Jelinek DF, Aagaard-Tillery KM, Arendt BK, Arora T, Tschumper RC, Westendorf JJ . Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression. J Clin Invest 1997; 99: 447–456.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Jelinek DF, Arora T . Effects of interferon alpha on myeloma cells: mechanisms of differential responsiveness. Curr Top Microbiol Immunol 1997; 224: 261–268.

    CAS  PubMed  Google Scholar 

  8. Blade J, Lopez-Guillermo A, Tassies D, Montserrat E, Rozman C . Development of aggressive plasma cell leukaemia under interferon-alpha therapy. Br J Haematol 1991; 79: 523–525.

    Article  CAS  PubMed  Google Scholar 

  9. Sawamura M, Murayama K, Ui G, Matsushima T, Tamura J, Murakami H et al. Plasma cell leukaemia with alpha-interferon therapy in myeloma. Br J Haematol 1992; 82: 631.

    Article  CAS  PubMed  Google Scholar 

  10. Lu ZY, Zhang XG, Rodriguez C, Wijdenes J, Gu ZJ, Morel-Fournier B et al. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood 1995; 85: 2521–2527.

    CAS  PubMed  Google Scholar 

  11. Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA, Jelinek DF . Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia 1996; 10: 866–876.

    CAS  PubMed  Google Scholar 

  12. Novak AJ, Bram RJ, Kay NE, Jelinek DF . Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002; 100: 2973–2979.

    Article  CAS  PubMed  Google Scholar 

  13. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 2005; 289: G960–G968.

    Article  CAS  PubMed  Google Scholar 

  14. Zitzmann K, Brand S, Baehs S, Goke B, Meinecke J, Spottl G et al. Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun 2006; 344: 1334–1341.

    Article  CAS  PubMed  Google Scholar 

  15. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004; 103: 689–694.

    Article  CAS  PubMed  Google Scholar 

  16. French JD, Walters DK, Jelinek DF . Transactivation of gp130 in myeloma cells. J Immunol 2003; 170: 3717–3723.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Diane Jelinek for the use of the KAS-6/1 and KP-6 cell line. This study supported in part by the National Institutes of Health Grants CA062242 and ZymoGenetics Inc. and Merck Serono International SA, an affiliate of Merck KGaA, Darmstadt, Germany.

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA

    A J Novak, D M Grote, S C Ziesmer, V Rajkumar & S M Ansell

  2. Department of Hematology and Oncology, ZymoGenetics Inc., Seattle, WA, USA

    S E Doyle

Authors
  1. A J Novak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D M Grote
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S C Ziesmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V Rajkumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S E Doyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S M Ansell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S M Ansell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Novak, A., Grote, D., Ziesmer, S. et al. A role for IFN-λ1 in multiple myeloma B cell growth. Leukemia 22, 2240–2246 (2008). https://doi.org/10.1038/leu.2008.263

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.263

Keywords

This article is cited by

Search

Advanced search

Quick links